Novo Nordisk's stock has plummeted after the company released a disappointing forecast, with some outlets citing a weak US pricing outlook for one of its products. The company's sales guidance has been cut, and there are concerns about competition, although some analysts still predict strong sales for the industry as a whole. The outlook for Novo Nordisk's stock is uncertain, with some predicting a potential rebound and others advising caution.